Drug intelligence / Profile preview

JK 50561

Development stage: Phase 2
Lead developer: Beijing Joekai Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

JK 50561 (also known as Inforget or simply "50561") is an orally available small molecule inhibitor of Rac1 (Ras-related C3 botulinum toxin substrate), a GTP-binding protein involved in cellular signaling pathways. The drug is being developed primarily for the treatment of Alzheimer's disease and other cognitive disorders. Its mechanism of action centers on inhibiting Rac1 activity, which may modulate neurodegenerative processes and vascular dysfunction associated with dementia. The developer and originator is Beijing Joekai Biotechnology[1][2]. As of August 2023, it has reached Phase II clinical trials for Alzheimer's disease and preclinical development for amnesia and vascular dementia[1].

Brand names: Inforget
Other names: 50561JK-50561JK50561JK 50561

Targets

RAC1 (Rac family small GTPase 1)

Beyond the preview

Go deeper on JK 50561.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JK 50561.

Explore the full profile